Smart Analysis and Decision-Making for Emerging Infectious Diseases

Sponsor
Peking University
Study ID
NCT07678619
Status
Enrolling By Invitation

Conditions

  • Avian Influenza
  • COVID-19
  • Chikungunya Fever
  • Dengue Fever
  • Emerging Infectious Diseases
  • Influenza
  • Mpox (Monkeypox)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases — OTHER
    The multi-agent integrated smart toolkit consists of four integrated agents: (1) Data-Knowledge Agent - for early risk perception based on historical event experience; (2) Assessment Agent - for risk assessment and situational analysis; (3) Decision Agent - for emergency decision support; and (4) Evaluation Agent - for effect simulation and comprehensive evaluation. The toolkit is designed to assist CDC staff with epidemic risk perception, situational assessment, and emergency decision-making. It is used alongside routine infectious disease prevention and control practices.
  • Routine Practices — OTHER
    Routine infectious disease prevention and control practices currently implemented at the CDC, including standard epidemic surveillance, information collection, risk assessment, and emergency response procedures.

Study Details

Emerging infectious diseases, such as COVID-19, mpox, and dengue fever, are characterized by rapid transmission, wide impact, and high uncertainty, posing ongoing threats to global public health. While China achieved significant success in COVID-19 control, the response also revealed key challenges, including fragmented information, delayed risk perception, experience-dependent assessment, and inefficiencies in complex decision-making. This study aims to establish a smart technology system covering the full chain of "risk perception-situational assessment-intelligent decision-making-comprehensive evaluation." Specific objectives include: Constructing a global disease burden database and knowledge graph for emerging infectious diseases; Developing early risk assessment models covering the full transmission spectrum (cross-species, imported, and local outbreak); Building an AI-driven collective intelligence decision-support tool for epidemic control; Developing precise intervention frameworks and comprehensive evaluation indicators for key populations (e.g., elderly, students); Integrating the above technologies into a multi-agent toolkit and evaluating its effectiveness through a cluster randomized controlled trial across 52 CDC sites in five provinces (Guangdong, Zhejiang, Hubei, Sichuan, and Shanghai). The study population includes public health professionals and managers responsible for epidemic surveillance, risk assessment, decision-making, and emergency response at the city/district/county CDC levels across the five provinces. Approximately 780 participants will be enrolled. The intervention group will use the smart toolkit alongside routine practices, while the control group will follow routine practices only. The primary outcome is response time for epidemic assessment and decision-making (hours from risk perception to decision completion). Secondary outcomes include epidemic control effectiveness, user satisfaction, and socioeconomic benefits. The intervention period is 3 months, starting around July 2026 and ending in December 2027. This study has been approved by the Peking University Biomedical Ethics Committee. The study does not involve individual patient data; all data are aggregated at the district/county level from CDC sources or publicly available data. Anonymous questionnaires do not collect any personal identifiable information.

Key Dates

First listed
Jul 1, 2026
Start date
Jul 17, 2026
Status verified
Jun 2026
Primary completion
Jul 17, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
780 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Intervention Group
    Participants in this arm will receive the multi-agent integrated smart toolkit, consisting of Data-Knowledge, Assessment, Decision, and Evaluation agents, in addition to routine infectious disease prevention and control practices. The toolkit is designed to assist CDC staff with epidemic risk perception, situational assessment, and emergency decision-making throughout the 3-month intervention period, alongside their routine CDC workflow.
  • Active Comparator: Control Group
    Participants in this arm will follow routine infectious disease prevention and control practices only, without access to the multi-agent integrated smart toolkit, including standard epidemic surveillance, information collection, risk assessment, and emergency response procedures currently implemented at their respective CDC, and will continue their regular workflow without any additional intervention during the 3-month study period.

Primary Outcome Measure

Response Time for Risk Assessment Report Generation and Submission [ Time Frame: Measured at baseline (enrollment) and at the end of the 3-month intervention period ]

Find similar trials

Nationwide
COVID-19 / long COVID trialsInfectious disease trials

Related Studies